Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02743494 · OUTCOME

Overall Survival Rates at 12-, 24-, and 36-months

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer · Source last updated 2025-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent of participants
Interval / dispersion
95% Confidence Interval
Time frame
At 12-, 24- and 36-months post first dose.

What was measured

Overall survival rate is defined as the percentage of participants who are alive at 1, 2 and 3 years following randomization

Analysis population: All randomized participants.

Groups in this outcome

Nivolumab

Nivolumab 240 mg Q2W for 8 cycles (16 weeks) followed by Nivolumab 480 mg Q4W for 9 cycles.

Placebo

Placebo IV Q2W for 8 cycles (16 weeks) followed by Placebo IV Q4W for 9 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab532
Placebo262

Reported measurements

12-months
Values in Percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab87.5Not reported84.490.0Not reported
Placebo84.6Not reported79.688.4Not reported
24-months
Values in Percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab68.1Not reported63.971.9Not reported
Placebo65.8Not reported59.671.2Not reported
36-months
Values in Percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Nivolumab56.9Not reported52.561.0Not reported
Placebo49.7Not reported43.555.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        84.4
        upper Limit
        90.0
        value
        87.5
      2. group Id
        OG001
        lower Limit
        79.6
        upper Limit
        88.4
        value
        84.6
    title
    12-months
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        63.9
        upper Limit
        71.9
        value
        68.1
      2. group Id
        OG001
        lower Limit
        59.6
        upper Limit
        71.2
        value
        65.8
    title
    24-months
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        52.5
        upper Limit
        61.0
        value
        56.9
      2. group Id
        OG001
        lower Limit
        43.5
        upper Limit
        55.7
        value
        49.7
    title
    36-months
denoms
  1. counts
    1. group Id
      OG000
      value
      532
    2. group Id
      OG001
      value
      262
    units
    Participants
description
Overall survival rate is defined as the percentage of participants who are alive at 1, 2 and 3 years following randomization
dispersion Type
95% Confidence Interval
groups
  1. description
    Nivolumab 240 mg Q2W for 8 cycles (16 weeks) followed by Nivolumab 480 mg Q4W for 9 cycles.
    id
    OG000
    title
    Nivolumab
  2. description
    Placebo IV Q2W for 8 cycles (16 weeks) followed by Placebo IV Q4W for 9 cycles
    id
    OG001
    title
    Placebo
param Type
NUMBER
population Description
All randomized participants.
reporting Status
POSTED
time Frame
At 12-, 24- and 36-months post first dose.
title
Overall Survival Rates at 12-, 24-, and 36-months
type
SECONDARY
unit Of Measure
Percent of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice